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 Introduction 
 Th e use of the phrase “ pilot study ” in clinical and translation 
research is widespread. A MedLine search of the term in the title 
of articles published during the past year alone (from January 
2010 through March 2011), for example, yielded over 19,000 
publications. Th rough our own work as members of biostatistics, 
epidemiology, and research design (BERD) resource units in 
institutions that have received Clinical and Translational Science 
Awards (CTSAs) from the National Institutes of Health, we have 
found that a high percentage of investigators seeking consultations 
have said they are either conducting or planning to conduct pilot 
studies. Th e purpose of our article is to provide a clear defi nition 
of a pilot study in the context of clinical and translational science 
and to off er recommendations about appropriate pilot study 
design. To achieve this goal, we fi rst present some commonly 
observed scenarios that are viewed as problematic or inappropriate 
application of the term “pilot” to describe the study. Th e paper 
concludes with the recommendations. 
 Common problematic scenarios 
 We defi ne “pilot studies” as preparatory studies designed to 
test the performance characteristics and capabilities of study 
designs, measures, procedures, recruitment criteria, and 
operational strategies that are under consideration for use in a 
subsequent, oft en larger, study. Although pilot studies are oft en 
considered less important than other studies, they require no 
less care in planning—particularly if they are to be published. 
Successful pilot studies provide optimal information needed 
to prepare for future studies and thereby help to move clinical 
and translational investigative careers forward. Th ere are several 
common scenarios in which misuse of the phrase  pilot study 
creates pitfalls. 
 First, the label “pilot study” is liberally applied to projects with 
little or no funding. Th is misuse stems from a self-perpetuating 
misconception that pilot status and lack of funding are mutually 
justifying. Th is view fails to recognize that the study’s design 
and scientifi c integrity are usually compromised by inadequate 
funding. Th e study is undermined when study coordination, 
technical expertise, database management, and biostatistical 
assistance are sacrifi ced. Th e sample size is oft en matched to the 
level of funding without regard to the likelihood of achieving the 
specifi c aims. As Perry emphasized, “Calling a study a pilot is no 
excuse for a small sample size or for inadequate methodological 
rigor.” 1 
 Second, the “pilot” label is oft en seen on vague, poorly 
developed research proposals. Common manifestations of 
this pitfall are vague research questions and poor alignment 
of the stated specifi c aims with the plans for statistical analyses 
and sample size justifi cation. For example, a misalignment has 
occurred when the stated aims are to evaluate recruitment 
feasibility and treatment tolerability, but the proposed analysis 
plan and sample size justifi cation focus on a hypothesis test 
of treatment effi  cacy. In some cases many outcomes (effi  cacy, 
surrogates, biomarkers) are described, and thus the study may 
be better described as exploratory, where the goal is hypothesis 
generation or refi ning existing hypotheses rather than testing 
feasibility. Th ese types of studies are particularly valuable for 
giving direction to future investigations. For the purposes of 
this manuscript we consider exploratory studies to be diff erent 
than pilot studies. 
 Th ird, in many cases, the apparent rationale for using the 
 pilot label is simply that the study precedes a more costly study. 
Th ese pilot study proposals do not provide any details about 
the subsequent study other than “the data from this pilot will 
inform a future larger R01-funded study.” Th e pitfall is that there 
is no assurance that the pilot study will provide the particular 
information needed to inform the successful design and execution 
of the subsequent study. Th e overarching research question and 
potential design of subsequent studies are critical elements in 
designing and justifying any proposed pilot study. 
 Finally, as CTSA BERD faculty members, we have observed 
that many junior clinical and translational investigators become 
involved in a nonproductive research strategy that involves 
designing and implementing a series of pilot studies that yield 
“negative” results ( p > 0.05) and are subsequently replaced by 
negative results from additional pilot studies ( Figure 1 ). Th e 
investigators do not take the time to publish what they have 
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learned from the pilot study because “they didn’t fi nd anything.” 
This endless cycle of poor staging of pilot studies without 
setting goals to move forward uses a substantial amount of the 
investigator’s time and resources and fails to advance scientifi c 
understanding and the investigator’s career. 
 Recommendations for investigators considering a pilot study 
 Here we provide recommendations concerning the preparatory 
relationship of the pilot study to one or more subsequent studies, 
protocol design and analysis for the pilot study, sample size 
considerations for the pilot and the future study, and the role of 
pilot studies in career development. We recommend that pilot 
study research proposals are best developed via the organization 
of a master protocol document which is updated throughout 
the course of the research and usually has sections specifying 
objectives, study design, enrollment and withdrawal, schedule, 
procedures and evaluations, safety and clinical monitoring, 
biostatistical considerations, database management plans, and 
quality assurance, and appendices of data collection instruments. 
A working document such as this serves as the basis for grant 
proposals and publications. 
1.  Keeping the Next Study in Mind 
 Clinical and translational research spans a spectrum of eff orts 
ranging from work at the molecular level to widespread testing 
of a treatment in a community setting. “Stages” of testing in 
drug development are highly accepted and implemented for 
drug development starting with preclinical studies followed by 
a progression of phase I through phase III clinical trials testing 
safety, effi  cacy, and eff ectiveness. Some of these trials are deemed 
“pivotal” and may be immediately preceded by a preparatory pilot 
study. At each step, the study design and statistical strategies are 
framed around research questions that are prerequisites for the 
next phase, but the overarching goal is testing the new drug for 
eff ectiveness in the targeted population. 
 In contrast to drug development, the “staging” or “sequencing” 
of studies is oft en not as well defi ned in when the research questions 
focus on nondrug intervention development or other areas where 
interventions are not being developed. We have observed in these 
settings that not enough attention is given to staging subsequent 
research studies. Investigators who are proposing a pilot study 
must have an understanding of the overarching research question 
and the stage of scientifi c evidence building that their study 
addresses. 1,2 Furthermore, they must understand whether the 
main purpose of their pilot study is to investigate a process 
(e.g., recruitment feasibility, protocol refi nement, willingness 
of physician to randomize or patient to be randomized) or an 
outcome (e.g., complication rates or effi  cacy measures). 
 Th e aims and methods of a pilot study must be aligned with 
the goals of the subsequent study. For example, in the fi eld of 
anticancer drug development, Schoenfeld 3 defi ned pilot studies as 
small, nonrandomized clinical trials with three major functions—
developing or refi ning the protocol for a new treatment, detecting 
unacceptable complication rates, and estimating potential effi  cacy 
relative to historical controls—all for the sole purpose of planning 
subsequent phase 3 studies. Dobkin 4 has argued for three stages 
of pilot studies to inform and strengthen implementation of a 
multicenter randomized trial. While Dobkin’s recommendations 
were focused on developing motor interventions for disabled 
patients, the recommendations are broadly applicable and mirror 
the traditional drug development paradigm. Th e three stages 
correspond to consideration-of-concept studies, development-
of-concept studies, and demonstration-of-concept pilot studies. 
Th is staging is advocated not only for a single study team but for 
groups of study teams working in the same area of intervention 
development. 
 In general, pilot studies contribute to the development and 
design of future, more costly, primary studies by clarifying and 
sharpening the research hypotheses to be studied, identifying 
relevant factors that could create barriers to subsequent study 
completion, evaluating the acceptability of methods and 
instruments to participants, measuring the time required for study 
participation, and providing concrete estimates of the expected 
rates of missing data and participant attrition. 5 
 2. Design the Pilot Study with Carefully Specifi ed Aims and 
Rationale 
 Objectives and aims 
 In practical research, the aims of small studies are oft en a mix 
of some of the following: pilot eff orts, exploratory eff orts, and 
defi nitive evaluations. For clarity in this report we consider only 
studies whose aims all concern “pilot study” objectives. 
 Pilot study aims should serve to identify and address issues 
that could occur with respect to future study conceptualization, 
study design, sample size, sample selection, data collection, data 
management, and data analysis. 6,7 Th e aims of pilot studies can 
range from evaluating the feasibility of protocol implementation 
to investigating the potential mechanisms of effi  cacy for a new 
intervention. 5–9 
 Once the aims are clearly defined, the specification of 
the primary outcome variables should follow. In some cases, 
the investigators will seek to generate preliminary data on an 
established outcome of interest. But if the investigators seek 
to validate feasibility or logistics, they must consider how to 
measure these constructs. Oft en, a feasibility or logistical aim 
can be distilled into a proportion. For example, if the time 
from disease onset to treatment is critical, as is the case with 
stroke treatment, a pilot study could quantify the number and 
proportion of patients who can undergo the steps of recruitment, 
informed consent, enrollment, and randomization within the 
time frame of interest. If the proportion is not high (e.g., >80%), 
the investigators will need to modify these steps to ensure study 
feasibility. 
 Figure 1.  Nonproductive scientifi c strategy involving the use of pilot studies. 
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 Study design 
 It is vital that the design of the pilot study be guided by the aims 
of the pilot study. Although virtually any type of design could be 
used, it is oft en advantageous for the design of the pilot study to 
be similar to that of the larger subsequent study, especially if the 
aim is to assess feasibility. It is also advantageous for the pilot 
study to recruit participants from the same study population 
that will be used for the subsequent study. 5 For example, if one 
of the aims of the pilot study is to obtain statistical estimates of 
interparticipant and intraparticipant variance parameters for a 
clinical outcome, the pilot study will require a study design that 
incorporates repeated measures and a group of participants drawn 
from the same population to be used in the subsequent study. 
 Th e following set of questions should be answered as a part of 
the design of the pilot study: (1) What will be the study design of 
the subsequent study? (2) What statistical strategies and methods 
will be used in the subsequent study? (3) What novel or untested 
information is needed to plan the subsequent study, and when will 
this information be needed? (4) Is the proposed design of the pilot 
study adequate to obtain the information? (5) What information 
cannot be obtained, and how will the lack of this information be 
handled? (6) What generalizable knowledge can be used to plan 
the pilot study or subsequent study? 
 Statistical analysis plan 
 Regardless of the type of study, the hallmark of a well-developed 
analysis plan is a carefully constructed strategy for achieving 
each aim. An outline of statistical methods for each aim can 
serve as a summary, but the details should be fully developed in 
written paragraphs. Analyses for pilot studies should mainly rely 
on estimation (point and interval estimation) and involve only 
limited hypothesis testing within the scope of the original aims. 
 In a pilot study, the aims should focus on endpoints other than 
effi  cacy and safety measurements. For example, they should focus 
on feasibility. In many cases, quantitative measures of feasibility 
are not employed. If the aims are well-defi ned in terms of useful 
measures, the statistical consideration section of a protocol can 
follow traditional outlines with details pertaining to endpoint 
defi nition, sample size justifi cation, planned analyses, and pilot-
specifi c considerations. Th ese include the justifi cation of the 
error rate selection, 3 accrual expectations, and plans to use the 
information to guide the design of the subsequent study. While 
these plans should be emphasized throughout the study protocol, 
the statistical considerations should provide a clear rationale to 
support the next steps in the study process, including “go versus 
no go” decisions. 
 Cook et al. described a well-designed pilot study for the 
prophylaxis of thromboembolism. Th ey judiciously chose to study 
120 subjects to refi ne their protocols and maximize the chances of 
identifying problems that may arise in the larger multicenter trial. 
Th eir analyses focused simply on estimating protocol adherence 
and recruitment rates, comparing observed estimates to ones that 
were specifi ed  a priori . 10 
 3. Justify the Choice of Sample Size 
 It is not unusual for study proposal reviewers to encounter a 
statement such as the following from an investigator: “No 
sample size justifi cation is needed because of the pilot nature 
of the proposed study.” On the contrary, proposals for pilot 
studies are not exempt from the need to have a clear and well-
reasoned rationale for the number of participants to be included. 
Alignment of the rationale with the scientifi c aims of the research 
is critical. 
 Choosing a sample size for pilot studies requires judgment 
and aims-specific considerations of the issues of practical 
feasibility, the details of the statistical analysis plans, and the 
research risks, including the risks that the study aims will not 
be achieved. Small samples may be appropriate for aims such as 
pilot-testing a data management system, demonstrating the ability 
to execute a specifi c research protocol, or testing acceptability and 
adherence to a new online disease management intervention. If 
the aim is to evaluate the feasibility of a protocol across multiple 
clinical sites, the study could require a small sample for each site 
but a relatively large total sample. In addition, it is important to 
keep in mind that some statistical methods are valid only for 
large samples. Writing a clear and compelling justifi cation for the 
proposed sample size therefore requires an intellectual analysis 
of the expected benefi ts, risks, and costs of the study and the 
knowledge of which statistical methods are optimal for the study. 
“Value of information” techniques are becoming more recognized 
as alternatives to traditional sample size estimation methods that 
oft en rely on imprecise parameter inputs. 11 
 Power calculations for hypothesis testing 
 Some pilot studies will require hypothesis testing to guide 
decisions about whether further research developments are 
needed before the larger subsequent study can be undertaken. 
For example, statistical hypothesis testing is appropriate for 
addressing research questions such as the following: Is the RNA 
assay more accurate and more precise than the antigen assay? Is 
the taste of a particular dietary supplement acceptable to at least 
95% of the target population? In cases such as this, the power 
of the hypothesis test will depend on the choice of sample size 
and will be a function of hypothesized parameter values. It will 
therefore be useful for the investigators to calculate the power 
when diff erent sample sizes are used. For example, sample sizes 
of 30, 50, and 70 provide 48%, 78%, and 84% power to detect 
an acceptance rate of 85% or lower if the true acceptance rate 
in the population is 95% using a one-sided binomial test of size 
 α = 0.05. 
 Th e literature on hypothesis testing provides formulae for 
power calculations in approaches that range from the simplest 
single-sample study to the most complex multilevel and multigroup 
longitudinal clinical trial. At a minimum, any approach requires 
specifi cation of the alpha (type I, false-positive) error rate to 
be considered, the smallest diff erence in the distribution of 
the outcome values or event rates to be considered meaningful 
(clinically important), and the expected variability in outcome 
values or event rates. 
 Schoenfeld 3 suggested that preliminary hypothesis testing 
for effi  cacy could be conducted with a high type I error rate 
(false positive rate up to 0.25) and that subsequent testing would 
provide a control over the chances of a false discovery in spite of 
the initial elevated error rate. He suggested that this approach 
could ensure that the aims of the pilot study are completed in a 
timely manner due to the use of a smaller sample size. If such 
an approach is taken, it is important to remember that a pilot 
study should not be designed to provide defi nitive evidence 
for a treatment eff ect. It should, on the contrary, be designed 
to inform the design of a larger more comprehensive study and 
to provide guidance as to whether the larger study should be 
conducted. 
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 A pilot study should be an important step within the context 
of a line of research that is hypothesis driven. Th is does not 
mean, however, that every pilot study must test a hypothesis. 
Th e investigators who propose pilot studies and the committee 
members who provide scientifi c reviews of the proposals oft en 
mistakenly presume that a power calculation is the appropriate 
criterion for choosing the sample size. But if the aims of the pilot 
study do not include any hypothesis tests, the power level of a test 
procedure is not a valid consideration for sample size. Whether 
or not the study includes a hypothesis test, what is always a valid 
consideration for sample size is the anticipated level of precision 
of statistical estimators (see  Estimates, Confi dence Intervals, and 
Anticipated Levels of Precision below). 
 Because some scientifi c review committees demand that power 
calculations be included in all study proposals, the investigators 
oft en feel compelled to include hypothesis tests that are not the 
real reason for conducting their pilot study. For example, the 
investigators may feel compelled to add a statistical test of effi  cacy 
in a pilot study that is actually intended to assess feasibility. In 
some cases, they compound the problem by providing power 
levels that are based on overly simplistic computations and are 
therefore diffi  cult to interpret. In other cases, they summarize 
the power analysis and include misleading phrases, such as “Th e 
study has 80% power if the treatment diff erence is…,” when in 
fact they should make it clear that the test procedure in question 
can be expected to detect a diff erence with high probability only 
if the magnitude of the treatment eff ect is unbelievably large in 
the target population. In other words, it is believed that the test 
has low power for diff erences that are smaller but yet clinically 
meaningful. 
 If investigators and committee members are focusing on 
expectations for a hypothesis test that is unimportant in the pilot 
study, they will lose sight of the contributions that the pilot study’s 
main aims are designed to make. Again, the primary point is that 
the sample size justifi cation should be based on considerations, 
calculations, and analyses that directly align with primary goals 
of the pilot study. 9 
 Estimates, confi dence intervals, and anticipated levels of 
precision 
 Pilot studies are oft en used to generate preliminary data to support 
funding applications or protocol development activities. While 
there are limitations to this approach, a well-designed pilot study 
can provide a statistical point estimate (sample estimate) of the 
population parameter (the true, unobservable value in the target 
population of patients). For example, the percentage of pilot study 
participants who tolerate a new treatment or the proportion of 
eligible patients who provide informed consent for participation 
would be representative of the tolerance or participation rates if all 
potential participants were studied. Providing a means to estimate 
these quantities enables early indicators of treatment tolerability 
and enrollment feasibility. However, there is statistical uncertainty 
that must be taken into consideration when the estimates are used 
to generalize the pilot study fi ndings. 
 Confi dence intervals (CI) represent a plausible range for 
the true population value by accounting for distributional 
assumptions. Th us, the use of confi dence intervals can play a 
major role in the sample size justifi cation and analysis plans 
for pilot studies. Of course, the utility of a confi dence interval 
is directly related to the range of the interval, since the range 
quantifi es the imprecision of a sample estimate. If a confi dence 
interval spans a large range of values, this means that there are 
many plausible values for the population parameter. In other 
words, the estimate is relatively imprecise. 
 While larger sample sizes will yield a more precise estimate, 
there is usually a nonlinear relationship between the CI width 
and the sample size ( N ). In the case of CI for population means 
or proportions, the width of the CI is proportional to the 
square root of 1/ N . As  N is increased from 5 to 10, the width 
of the CI will decreased sharply; however, as  N is increased 
from 10 to 15, a slightly smaller decrease in width will be 
observed. Eventually, further increases in N have diminishing 
benefit on precision and those decreasing benefits become 
outweighed by practicalities such as time for recruitment and 
funding limitations. van Belle 12 and Julious 13 discussed cases 
in which increasing the sample size to 12 participants made 
a profound difference in the width of confidence intervals 
for mean response, whereas increasing the sample size 
beyond 12 participants did not. They referred to this result 
as a “rule of 12” for continuous variables. We recommend at 
least 12 participants for pilot studies with primary focus of 
estimating average values and variability for planning larger 
subsequent studies. This size is quite practical for most early-
stage investigators to conduct within single centers while still 
providing valuable preliminary information. 
 In other cases, the aims of a pilot study are defi ned in terms of a 
binary outcome such as compliance with a protocol or occurrence 
of an adverse event. For planning these types of studies, anticipated 
confi dence interval widths can be considered for potential sample 
sizes. For example, if the observed compliance rate in a pilot study 
was 80%, then the observed exact confi dence interval width would 
be 30% if  n = 30, or 20% if  n = 70. Confi dence intervals play an 
important role when all or nearly all of the participants satisfy 
(or do not satisfy) a criterion such as compliance or intolerance. 
Confi dence intervals based on binomial theory are able to convey 
the realistic level of uncertainty about such point estimates when 
planning these studies. 14–16 For example, if  n = 5 participants 
are observed to experience 0 events, the 90% exact upper limit 
for the event rate would be 37%, i.e., CI is [0%, 37%]. If  n = 10 
participants experience 0 events, the CI is [0%, 21%]. For  n = 20, 
the 90% CI is [0%, 11%]. Th e investigator must decide what level 
of precision is acceptable based on consideration of the stage of 
investigation (evidence needed), risk to the participant, time 
for study completion, and cost of the study. Better precision in 
the pilot study will provide greater confi dence when planning a 
subsequent study. 
 Additional considerations 
 In the simplest setting, sample size analyses for a two group clinical 
trial with a continuous outcome require inputs for Type I and 
Type II error rates, hypothesized means for each group at the 
end of the trial, and the standard deviation(s) of the outcome. A 
good use of a pilot study is to obtain estimates of control group 
means ( μ C ) and group-specifi c outcome variability for sample size 
analyses, including calculations of anticipated levels of precision 
and perhaps power, to be included in larger subsequent studies. Th e 
point estimates and confi dence intervals for the population control 
group mean and standard deviations ( σ ) should be calculated to 
identify plausible values of  μ C and  σ . Th ese estimates and their 
confi dence intervals should be combined with estimates from 
existing literature to provide a range of possible parameter values. 
Browne 17 recommends using an upper one-sided confi dence limit 
336 VOLUME 4 • ISSUE 5 WWW.CTSJOURNAL.COM
 Moore et al.   Planning Pilot Studies
(σ̂  UCL ) of at least 80% for standard deviation inputs from pilot 
studies. As Browne 17 noted, if the investigator “simply uses the 
[observed] sample standard deviation from a small pilot sample, 
the chances of actually achieving the planned power may be as 
low as 40%.” Browne’s approach takes into account the stochastic 
nature of the data from the pilot study as well as the stochastic 
nature of the data from the subsequent study. 
 As stated previously, the sample size analyses for a two 
group clinical trial with a continuous outcome require inputs 
for hypothesized means for each group at the end of the trial. Th e 
input for the intervention group mean should be the clinically 
meaningful value that is truly hypothesized at the end of the 
study if the intervention is eff ective. 18–21 Th e group means can 
be used to calculate an eff ect size by taking their diff erence and 
dividing by the standard deviation of the outcome. In the special 
situation of pilot clinical trials, the power analysis for that larger 
trial should not be based on the estimated eff ect ( μ̂, the observed 
mean diff erence) or the eff ect size from the pilot study. 22 If the 
estimate was large in the pilot study, using it would result in 
largely underpowered trials. Also, the decision to move forward 
to a larger trial should not solely be based on the estimated eff ect 
size from the pilot study. If the estimate was small in the pilot 
study, using it would result in a high likelihood of not investigating 
truly effi  cacious interventions.22 Because pilot clinical trials 
are usually small, they have a high likelihood of imbalances at 
baseline, leading to unreliable estimates of treatment eff ects. 9 
And because study populations in pilot clinical trials are typically 
enrolled within a single study site, the participant population 
tends to be more homogeneous than that typically enrolled in 
larger trials and thus contributes to the optimistic overestimation 
of treatment eff ects. 
 Multiple pilot studies may be conducted prior to a larger 
multicenter clinical trial which test feasibility of the intervention 
and short-term mechanistic outcomes. Using this approach, 
nonrandomized or randomized pilot studies of feasibility for 
the intervention(s) should be conducted prior to a randomized 
controlled pilot clinical trial. Much can be learned from the 
feasibility study that may change the population, intervention, 
protocol, outcomes, etc., possibly requiring an additional 
pilot study if a substantial modifications are made. Once 
the intervention is fi nalized and well defi ned from the pilot 
studies, a mechanistic pilot randomized clinical trial (proof-
of-principle) may be planned with the targeted mechanism as 
the primary outcome and sample size analyses based on that 
outcome. “Pilot studies” that propose a test for potential effi  cacy 
for patient relevant outcomes should be designed as Phase II 
studies using the single-arm or multiple-arm study design and 
methodology that best answers the research question. 23,24 Th ese 
studies are oft en planned and conducted using higher levels of 
type of I rates (10–25%) which are consistent with “screening 
for potential effi  cacious treatments” to be tested subsequently in 
larger trials. Type II error rates should be kept lower ( β  10%) 
to protect against not putting forward benefi cial interventions 
for additional testing. 
 4. Pilot Studies and Career Trajectories 
 At institutions that have a CTSA from the National Institutes of 
Health, funding is available for clinical and translational pilot 
studies. Th ese studies are intended to allow investigators to 
obtain preliminary data and refi ne procedures and hypotheses 
to develop protocols for more defi nitive subsequent studies and 
to generate grant proposals for funding from national agencies. In 
this context, the investigators must be able to propose a productive 
trajectory for their research agenda, which means that they must 
have the protocol for the future study in mind when they are 
planning the initial study. 
 For junior and developing investigators, the benefits of 
pilot-funded studies are numerous. A pilot study can provide 
an ideal opportunity to gain experience with new procedures, 
new collaborations, protocol writing, funding applications, and 
institutional review board applications. Th e preliminary data 
from a pilot study is critical for convincing funding bodies that 
the science proposed is feasible and that the study investigator 
is competent. In this regard, the scientifi c rigor demonstrated 
during preliminary investigations oft en serves as a surrogate for 
scientifi c rigor in a more confi rmatory setting. 
 Pilot-funded studies can provide a time-effi  cient mechanism 
for professional development but only if their scientifi c rigor is 
not compromised. A danger here is that a long series of pilot 
studies without the subsequent confi rmatory studies may be 
detrimental to an investigator’s career, especially if there is not a 
clear research theme. To avoid this problem, investigators should 
be encouraged to publish their results from pilot studies with 
absolute transparency of the purpose of the study. 25 Regardless 
of whether the pilot studies yield positive or negative results, 
they can provide valuable information for future research with 
respect to design, methods, and instruments. 5 Unfortunately, 
many investigators make little or no eff ort to publish negative 
or unsuccessful fi ndings, and this contributes to publication 
bias. 26 
 When authors are preparing their work for publication, 
they should identify their work as a pilot study throughout 
the manuscript, including in the title, research questions, 
methodology, and interpretations. 1 It is worth emphasizing here 
that the goal of publishing results from pilot studies is not to focus 
on the statistically signifi cant fi ndings but, rather, to provide 
estimated eff ects (point estimates with confi dence intervals) 
for all measures of interest and to describe the lessons that have 
been learned and will be informative in planning subsequent 
studies. 
 Summary 
 Pilot studies are preparatory investigations that provide specifi c 
information needed for planning subsequent studies. In many 
cases, they are designed to test the performance characteristics 
and capabilities of study designs, measures, procedures, 
recruitment criteria, and operational strategies that are under 
consideration for use in a larger subsequent study. They 
provide the means to evaluate the technical aspects of novel 
approaches while serving as a platform to generate preliminary 
data and foster investigator development. To make sure that 
the information gained through pilot studies can be put to 
optimal use in a series of studies that build on scientifi c evidence, 
investigators must be extremely clear about the purpose of each 
pilot studies they are planning and must always keep in mind 
the overarching research question that they will be addressing in 
their future studies. Although we provided general information 
about sample size justifi cation using power calculations and 
precision, we strongly encourage investigators to work with a 
biostatistician in developing the aims, study design, analysis 
plan, and sample size justifi cation since each study has its unique 
aspects that need to be considered. 
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